NASDAQ:LYRA Lyra Therapeutics (LYRA) Stock Price, News & Analysis → His win rate puts Warren Buffett to shame… (From Investing Daily) (Ad) Free LYRA Stock Alerts $4.72 -0.45 (-8.70%) (As of 04/26/2024 08:52 PM ET) Add Compare Share Share Today's Range$4.70▼$5.2050-Day Range$4.72▼$6.5352-Week Range$2.26▼$6.79Volume157,200 shsAverage Volume310,752 shsMarket Capitalization$281.97 millionP/E RatioN/ADividend YieldN/APrice Target$12.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Lyra Therapeutics alerts: Email Address Lyra Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside168.4% Upside$12.67 Price TargetShort InterestHealthy0.56% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.07Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.04) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.02 out of 5 starsMedical Sector583rd out of 915 stocksSurgical & Medical Instruments Industry68th out of 95 stocks 3.5 Analyst's Opinion Consensus RatingLyra Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLyra Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.56% of the outstanding shares of Lyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently increased by 49.60%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLyra Therapeutics does not currently pay a dividend.Dividend GrowthLyra Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LYRA. Previous Next 1.7 News and Social Media Coverage News SentimentLyra Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Lyra Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for LYRA on MarketBeat in the last 30 days. This is a decrease of -93% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Lyra Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.42% of the stock of Lyra Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Lyra Therapeutics are expected to decrease in the coming year, from ($1.04) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyra Therapeutics is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyra Therapeutics is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyra Therapeutics has a P/B Ratio of 3.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Investing DailyHis win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Lyra Therapeutics Stock (NASDAQ:LYRA)Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Read More LYRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LYRA Stock News HeadlinesApril 26, 2024 | globenewswire.comLyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 26, 2024 | newsweek.comWorld's Best Digital Health Companies 2024 - TreatmentApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 26, 2024 | finance.yahoo.comPrivate equity firms who hold 39% of Lyra Therapeutics, Inc. (NASDAQ:LYRA) gained 6.8%, institutions profited as wellMarch 23, 2024 | finance.yahoo.comLyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS ProjectionsMarch 22, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lyra Therapeutics’ LYR-210 Amidst Phase 3 Trial and Market OpportunityMarch 22, 2024 | msn.comLyra Therapeutics files for $300M mixed shelfMarch 21, 2024 | globenewswire.comLyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateApril 29, 2024 | Investing Daily (Ad)His win rate puts Warren Buffett to shame… Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 15, 2024 | finance.yahoo.comLYRA Jul 2024 2.500 callMarch 15, 2024 | finance.yahoo.comLYRA Jul 2024 7.500 callMarch 15, 2024 | finance.yahoo.comLYRA Apr 2024 7.500 putMarch 15, 2024 | finance.yahoo.comLYRA May 2024 7.500 callMarch 1, 2024 | globenewswire.comLyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 21, 2024 | finance.yahoo.comHere's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price StrengthFebruary 12, 2024 | bizjournals.comLyra Therapeutics invests in Mass. manufacturing with new HQJanuary 29, 2024 | businessinsider.comThese are the 7 healthcare startups primed to IPO when the market reopensJanuary 28, 2024 | msn.com15 Unhappiest States in the USJanuary 17, 2024 | finance.yahoo.comWhat Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing'December 27, 2023 | benzinga.comLyra Therapeutics Stock (NASDAQ:LYRA) Dividends: History, Yield and DatesNovember 15, 2023 | finance.yahoo.comExecutive Chairman of Lyra Therapeutics Harlan Waksal Buys 11% More SharesNovember 15, 2023 | finance.yahoo.comLyra Therapeutics Insider Ups Holding By 11% During YearNovember 14, 2023 | benzinga.comExecutive Chair of Lyra Therapeutics Purchased $74K In StockNovember 11, 2023 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Lyra Therapeutics, Inc. (NASDAQ: LYRA) and Encourages Investors to Contact the FirmNovember 7, 2023 | msn.comLyra Therapeutics GAAP EPS of -$0.27, revenue of $544MNovember 7, 2023 | finance.yahoo.comLyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 16, 2023 | benzinga.comLyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal OfficerSee More Headlines Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today4/29/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:LYRA CUSIPN/A CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees88Year FoundedN/APrice Target and Rating Average Stock Price Target$12.67 High Stock Price Target$15.00 Low Stock Price Target$11.00 Potential Upside/Downside+168.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,680,000.00 Net Margins-4,023.11% Pretax Margin-4,019.32% Return on Equity-72.62% Return on Assets-50.90% Debt Debt-to-Equity RatioN/A Current Ratio5.35 Quick Ratio5.35 Sales & Book Value Annual Sales$1.56 million Price / Sales180.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book3.03Miscellaneous Outstanding Shares59,740,000Free Float49,336,000Market Cap$281.97 million OptionableOptionable Beta0.23 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Harlan W. Waksal M.D. (Age 71)Executive Chairman Comp: $210.06kDr. Maria Palasis Ph.D. (Age 59)CEO, President & Director Comp: $942.7kDr. John E. Bishop Ph.D. (Age 62)Chief Technology Officer Comp: $662.9kDr. Carmichael S. Roberts Jr. (Age 55)Ph.D., Co-Founder Mr. Jason Cavalier (Age 51)CFO, Treasurer & Secretary Comp: $464.11kMr. Ray KnoxVice President of OperationsMs. Ellen CavaleriSenior Vice President of Investor Relations & CommunicationsMr. Ronan P. O'Brien J.D. (Age 51)Chief Legal Officer Ms. Corinne Noyes (Age 56)Senior Vice President of Commercial Strategy & Market Development Comp: $426.73kMs. Vineeta Belanger Ph.D.Senior Vice President of Clinical AffairsMore ExecutivesKey CompetitorsFractyl HealthNASDAQ:GUTSCVRxNASDAQ:CVRXCerusNASDAQ:CERSPulmonxNASDAQ:LUNGBioventusNYSE:BVSView All CompetitorsInsiders & InstitutionsRosalind Advisors Inc.Sold 744,196 shares on 4/25/2024Ownership: 1.916%Parkman Healthcare Partners LLCBought 129,829 shares on 2/15/2024Ownership: 1.436%Vestal Point Capital LPBought 3,000,000 shares on 2/14/2024Ownership: 5.708%Armistice Capital LLCSold 462,000 shares on 2/13/2024Ownership: 2.070%Jump Financial LLCBought 16,737 shares on 2/7/2024Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions LYRA Stock Analysis - Frequently Asked Questions Should I buy or sell Lyra Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyra Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LYRA shares. View LYRA analyst ratings or view top-rated stocks. What is Lyra Therapeutics' stock price target for 2024? 4 brokerages have issued 1-year price targets for Lyra Therapeutics' stock. Their LYRA share price targets range from $11.00 to $15.00. On average, they anticipate the company's share price to reach $12.67 in the next year. This suggests a possible upside of 168.4% from the stock's current price. View analysts price targets for LYRA or view top-rated stocks among Wall Street analysts. How have LYRA shares performed in 2024? Lyra Therapeutics' stock was trading at $5.24 at the start of the year. Since then, LYRA shares have decreased by 9.9% and is now trading at $4.72. View the best growth stocks for 2024 here. Are investors shorting Lyra Therapeutics? Lyra Therapeutics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 333,600 shares, an increase of 49.6% from the March 31st total of 223,000 shares. Based on an average daily volume of 336,700 shares, the days-to-cover ratio is presently 1.0 days. View Lyra Therapeutics' Short Interest. When is Lyra Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our LYRA earnings forecast. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (NASDAQ:LYRA) issued its quarterly earnings results on Thursday, March, 21st. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.11. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.52 million. Lyra Therapeutics had a negative net margin of 4,023.11% and a negative trailing twelve-month return on equity of 72.62%. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lyra Therapeutics investors own include Pfizer (PFE), DocuSign (DOCU), Intel (INTC), OPKO Health (OPK), Valero Energy (VLO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Gilead Sciences (GILD), Micron Technology (MU) and ONEOK (OKE). When did Lyra Therapeutics IPO? Lyra Therapeutics (LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair acted as the underwriters for the IPO and BTIG was co-manager. Who are Lyra Therapeutics' major shareholders? Lyra Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Rosalind Advisors Inc. (1.92%). Insiders that own company stock include C Ann Merrifield, Edward T Anderson, Harlan Waksal, Mukesh Mehta, Nbvm Gp, Llc and Perceptive Advisors Llc. View institutional ownership trends. How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LYRA) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupHis win rate puts Warren Buffett to shame… Investing DailyTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
